A Message from Veracyte’s CEO About COVID-19     Learn More
A Message from Veracyte’s CEO About COVID-19     Learn More
Skip to content
PRESS RELEASES

PRESS RELEASES

Date Title and Summary Additional Formats
Toggle Summary Veracyte Announces Preliminary First Quarter 2020 Financial Results and Provides Business Update in Response to COVID-19 Pandemic
Expects first quarter revenue in the range of $30.5 million to $31.5 million Withdraws full-year 2020 guidance SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Apr. 16, 2020-- Veracyte, Inc . (Nasdaq: VCYT) today announced preliminary, unaudited and unreviewed financial results for the first quarter
View HTML
Toggle Summary Veracyte Names Tracy Morris as Vice President of Corporate Communications and Investor Relations
Company also announces that Alfred “Freddie” Bowie, Jr., Ph.D. has been named to Savoy Magazine’s “2020 Most Influential Black Executives in Corporate America” List SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Apr. 7, 2020-- Veracyte, Inc. (Nasdaq: VCYT) today announced that it has named Tracy
View HTML
Toggle Summary Veracyte Announces Novel Gene Fusion Detection with the Afirma Xpression Atlas, Which May Inform Targeted Treatment Decisions for Thyroid Cancer Patients
Company launches expanded content to detect novel NTRK, ALK, RET and BRAF fusions at time of diagnosis SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Apr. 1, 2020-- Veracyte, Inc. (Nasdaq: VCYT) today announced results of a study that identified over 100 novel or rare NTRK, ALK, RET and BRAF
View HTML
Toggle Summary Veracyte Announces Publication of Nearly 700-Patient Study Using Prosigna Breast Cancer Test to Identify Patients Likely to Benefit from Aggressive Chemotherapy
Findings Based on Randomized Study of Danish Women with High-Risk, Early Breast Cancer Published in npj Breast Cancer SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)-- Veracyte, Inc. , (Nasdaq: VCYT) today announced the publication of a large, retrospective study in which the Danish Breast Cancer
View HTML
Toggle Summary Veracyte Announces Fourth Quarter and Full-Year 2019 Financial Results and Provides 2020 Financial Outlook
2019 Total Revenue Grew 31% to $120.4 Million ; Genomic Test Volume Grew 25% to 39,612 Achieved Fourth Quarter 2019 Positive Cash Flow from Operations Fourth Quarter Acquisition Positions Company for Global Expansion Conference Call and Webcast Today at 5:00 p.m. ET SOUTH SAN FRANCISCO, Calif.
View HTML
Toggle Summary Veracyte to Present at the 9th Annual SVB Leerink Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Feb. 13, 2020-- Veracyte, Inc . (Nasdaq: VCYT) announced today that Bonnie H. Anderson , chairman and chief executive officer, is scheduled to present at the 9th Annual SVB Leerink Global Healthcare Conference in New York City on Thursday, February 27,
View HTML
Toggle Summary Veracyte to Release Fourth Quarter and Full-Year 2019 Financial Results on February 25, 2020
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Feb. 6, 2020-- Veracyte, Inc . (Nasdaq: VCYT) announced today that it will release its financial results for the fourth quarter and full-year 2019 after the close of market on Tuesday, February 25, 2020 .
View HTML
Toggle Summary Veracyte Announces Biopharmaceutical Collaboration with Acerta Pharma
Agreement enabled by Veracyte acquisition of NanoString diagnostics assets for global expansion SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jan. 8, 2020-- Veracyte (Nasdaq: VCYT) today announced a multi-year partnership with Acerta Pharma, the hematology research and development arm of
View HTML
Toggle Summary Veracyte Acquires Exclusive License to NanoString Diagnostics Platform, Positioning Veracyte To Expand Its Genomic Testing Business Globally
Strategic transaction enables Veracyte to access global markets through a world-class, distributed instrument system, with an initial focus on its pulmonology franchise Provides pathway for long-term revenue growth and margin expansion Veracyte to hold conference call and webcast today at 5:30 p.m.
View HTML
Toggle Summary Veracyte Announces New Data That Advance Understanding of Genomic Alterations Targeted by Precision Medicine Therapies for Thyroid Cancer
Findings Presented at 89 th Annual Meeting of the American Thyroid Association SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Nov. 2, 2019-- Veracyte, Inc . (Nasdaq: VCYT) today announced new data that advance understanding of the frequency, positive predictive value and co-occurrence of genomic
View HTML